Research programme: anthrax therapy - Advanced BiosystemsAlternative Names: Anthrax therapy research programme - Advanced Biosystems
Latest Information Update: 13 Oct 2006
At a glance
- Originator Advanced Biosystems
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Anthrax
Most Recent Events
- 01 Jun 2006 No development reported - Preclinical for Anthrax in USA (unspecified route)
- 05 Jul 2002 Hadron is now called Alanex Corporation
- 27 Jun 2001 Preclinical development for Anthrax in USA (Unknown route)